HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 27, 20251-20254, July 7, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/27/20251    most recent C000228200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murata, H. Articles by Mueckler, M. Search for Related Content PubMed PubMed Citation Articles by Murata, H. Articles by Mueckler, M. Social Bookmarking                      What's this?

ACCELERATED PUBLICATION
The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy^*

Haruhiko Murata^§, Paul W. Hruz^§¶, and Mike Mueckler

From the  Department of Cell Biology and Physiology, ^¶ Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110

Received for publication, April 4, 2000, and in revised form, May 3, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Retroviral protease inhibitors used as therapy for HIV-1 infection have been causally associated with serious metabolic side effects, including peripheral lipodystrophy, hyperlipidemia, insulin resistance, and in some cases, overt type 2 diabetes. The etiology of this characteristic clinical syndrome remains unknown. We demonstrate that the HIV protease inhibitor, indinavir, dramatically inhibits insulin-stimulated glucose uptake in 3T3-L1 adipocytes in a dose-dependent manner (63% inhibition observed with 100 µM indinavir). Indinavir treatment did not affect early insulin signaling events or the translocation of intracellular Glut1 or Glut4 glucose transporters to the cell surface. To determine whether indinavir may be directly affecting the intrinsic transport activity of glucose transporters, the Glut1 and Glut4 isoforms were heterologously expressed and analyzed in Xenopus laevis oocytes. Indinavir at 100 µM had no effect on Glut1 transport activity in Xenopus oocytes, whereas Glut4 activity was significantly inhibited (45% inhibition). Similar effects on glucose transport were observed for other HIV protease inhibitors. We conclude that HIV protease inhibitors as a class are capable of selectively inhibiting the transport function of Glut4 and that this effect may be responsible for a major iatrogenic complication frequently observed in HIV patients.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

The human immunodeficiency virus (HIV)¹ encodes within its genome an aspartyl protease that is required to process its viral precursor polyproteins. This protease activity is essential for the proper formation of infectious HIV virions (1). The recent development of specific agents that target the HIV protease represents an extraordinary advance in the treatment of HIV infection. As part of a combination therapy, HIV protease inhibitors play a critical role in suppressing viral titers and increasing CD4⁺ lymphocyte counts, which translate to significantly reduced morbidity and mortality among HIV patients (2). Unfortunately, it now appears clear that protease inhibitor use is associated with a potentially serious syndrome of metabolic abnormalities characterized by peripheral fat wasting, central adiposity, hypertriglyceridemia, hypercholesterolemia, and insulin resistance (3-5). Hyperlipidemia and insulin resistance appear to occur at high prevalence among patients using protease inhibitors such that increased risk of premature cardiovascular disease and diabetes becomes a relevant issue (6). The prevalence of lipodystrophy has been reported to be as high as 83% according to one study (3, 5). The etiology of this metabolic syndrome associated with protease inhibitor use currently remains unknown, but its features are similar to those present in the insulin-resistant state commonly referred to as Syndrome X (7).

Recent studies have demonstrated that glucose transport into muscle is a rate-limiting step in whole body glucose disposal (reviewed in Ref. 8). Insulin acutely stimulates glucose uptake in muscle (9-12) and fat (13-15). These tissues express both the Glut1 (16, 17) and Glut4 (18-21) glucose transporter isoforms, although the latter is the predominant species. Upon insulin binding, the intrinsic tyrosine kinase activity of the insulin receptor is activated, which in turn initiates a complex signaling cascade (22). The downstream activation of a wortmannin-sensitive PI 3-kinase appears to be essential for the metabolic effects of insulin (22, 23). Ultimately, insulin signaling impinges on intracellular Glut4 vesicles, causing their rapid exocytosis and fusion with the plasma membrane (9, 13, 14). This phenomenon, known as Glut4 translocation, can account for most of the increase in cellular glucose uptake capacity stimulated by insulin in fat (24, 25) and muscle (26). Glut1 appears to contribute primarily to basal glucose uptake in both tissues (11, 24, 27).

These observations suggest a possible mechanism by which HIV protease inhibitors might induce insulin resistance. The purpose of this study was to address whether or not HIV protease inhibitors can directly affect the facilitated transport of glucose into insulin-responsive cells. We demonstrate here that HIV protease inhibitors selectively and potently decrease the intrinsic transport activity of the insulin-regulated glucose transporter isoform Glut4 without substantially affecting early insulin signaling events or Glut4 translocation. The clinical ramifications of this finding are discussed.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

Materials-- Indinavir, ritonavir, and amprenavir were obtained from Merck, Abbott, and Glaxo Wellcome, respectively. Xenopus laevis imported African frogs were purchased from Xenopus Express (Homasassa, FL). All other reagents unless otherwise specified were obtained from Sigma.

Cell Culture of 3T3-L1 Adipocytes-- 3T3-L1 fibroblasts obtained from the American Type Culture Collection were grown to confluence and 48 h later subjected to the differentiation protocol described previously (28). Mature 3T3-L1 adipocytes were maintained in DMEM supplemented with 10% fetal bovine serum and used 10 to 15 days post-differentiation.

2-Deoxyglucose Uptake Measurements in 3T3-L1 Adipocytes-- 3T3-L1 adipocytes grown in 3.5-cm dishes were serum-starved for at least 3 h and then washed three times with Krebs-Ringer phosphate buffer. [³H]2-Deoxyglucose uptake (50 µM cold 2-deoxyglucose) was measured in Krebs-Ringer phosphate buffer as described previously (28) for 6 min at 37 °C under basal and insulin-stimulated conditions (1 µM insulin for 20 min). When indicated, HIV protease inhibitors (indinavir, ritonavir, or amprenavir) were added to the cells at various concentrations 6 min prior to the assay. Stock solutions of indinavir and amprenavir were made in water. Ritonavir was dissolved in ethanol. When adding ritonavir to cells, the final concentration of ethanol was less than 0.5%. Nonspecific uptake was measured in the presence of 20 µM cytochalasin B and subtracted from the experimental values.

Subcellular Fractionation of 3T3-L1 Adipocytes-- 3T3-L1 adipocytes were grown in 10-cm dishes and incubated at 37 °C for 4 h in serum-free DMEM in the absence or presence of 100 µM indinavir. After treatment with or without insulin (1 µM for 20 min), the cells were scraped in ice-cold HES buffer (20 mM HEPES, pH 7.4, 255 mM sucrose, and 1 mM EDTA) supplemented with 100 mM sodium fluoride, 10 mM sodium pyrophosphate, 1 mM sodium vanadate, and general protease inhibitors (1 µg/ml leupeptin, 1 µg/ml antipain, 5 µg/ml trypsin inhibitor, 1 µg/ml chymostatin, 1 µg/ml pepstatin A, and 0.5 mM phenylmethylsulfonyl fluoride). After homogenization through 11 passes in a Yamato LSC homogenizer (1200 rpm) at 4 °C, subcellular fractionation by differential centrifugation was performed as described previously (29).

Immunoblot Analysis-- 3T3-L1 adipocyte fractions were subjected to SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose. Glut1 and Glut4 transporters were detected using polyclonal antibodies raised against peptides corresponding to the carboxyl-terminal 16 residues of the respective transporter isoform. The autoradiographic signals were quantitated by using a PhosphorImager (Molecular Dynamics). Phosphotyrosine-containing proteins were detected using the monoclonal PY-20 antibody (Transduction Laboratories). Phospho-Akt specific antibodies (New England Biolabs) were used to detect Akt phosphorylated at threonine 308 and serine 473.

Confocal Immunofluorescence Microscopy-- 3T3-L1 adipocytes were grown on no. 1 glass coverslips. Cells were incubated in the absence or presence of 100 µM indinavir as described above for subcellular fractionation. After treatment with or without insulin (1 µM for 20 min), whole cells were fixed immediately in 4% paraformaldehyde and permeabilized using methanol. PM sheets adherent to the coverslip were prepared by gentle sonication as described previously (30) and subsequently fixed using 4% paraformaldehyde. Glut1 and Glut4 subcellular distributions in the prepared coverslips were visualized by indirect immunofluorescence microscopy using isoform-specific polyclonal antibodies essentially as described previously (30). Images were taken using a Bio-Rad MRC-1024 laser scanning confocal microscope.

2-Deoxyglucose Uptake Measurements in Xenopus Oocytes-- X. laevis oocytes were prepared and injected as described previously (31) with 50 ng of either Glut1 or Glut4 mRNA synthesized in vitro (Megascript RNA synthesis kit, Ambion). After a 3-day incubation in Barth's saline containing albumin at 18 °C, groups of 15-20 oocytes were washed, and [³H]2-deoxyglucose (50 µM) uptake measurements were performed in Barth's saline at 22 °C for 30 min. HIV protease inhibitors (indinavir, amprenavir, or ritonavir) were added to the assay mixture immediately prior to the uptake measurement.

	RESULTS AND DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

We initially examined the effect of the HIV-1 protease inhibitor indinavir on glucose uptake in 3T3-L1 adipocytes, a system that responds robustly to insulin. When 3T3-L1 adipocytes were treated with indinavir, a statistically significant dose-dependent decrease in insulin-stimulated glucose uptake was observed with an inhibition of 63% at the maximal concentration of indinavir tested (100 µM; Fig. 1A). At 10 µM, which is within the physiologic range of plasma concentrations achieved in vivo in HIV patients (2), indinavir inhibited insulin-stimulated glucose uptake by 26% (p < 0.0001, ANOVA with Fisher PLSD posthoc analysis). Basal glucose uptake was largely unaffected by indinavir, although at 20 µM a modest increase was reproducibly observed. The inhibitory effect of indinavir on insulin-stimulated glucose uptake was very rapid as the drug was added to the cells only 6 min prior to the uptake assay. Furthermore, removal of indinavir rapidly restored normal insulin-responsive glucose uptake within 30 min (data not shown). Inhibition of insulin-stimulated glucose uptake appears to be a general property of HIV-1 protease inhibitors, as two other compounds within this class, amprenavir and ritonavir, also exhibited an effect comparable with that of indinavir (Fig. 1B).

View larger version (21K): [in this window] [in a new window]   Fig. 1.   The effect of HIV protease inhibitors on glucose uptake in 3T3-L1 adipocytes. A, indinavir sulfate was added to a final concentration of 10, 20, 50, and 100 µM as indicated 6 min prior to the glucose uptake assay. [3H]2-Deoxyglucose uptake was measured for 6 min at 37 °C under basal and insulin-stimulated conditions (1 µM insulin for 20 min). The data, representative of three independent experiments, are normalized to the value obtained from insulin-stimulated control cells and are shown as the mean ± S.E. (n = 6). B, 3T3-L1 adipocytes were treated with amprenavir, indinavir, and ritonavir at 50 µM concentration, and 2-deoxyglucose uptake was measured as described above. The data are normalized to the value obtained from insulin-stimulated control cells and are shown as the mean ± S.E. (n = 3).

Immunoblot analysis of 3T3-L1 adipocyte subcellular fractions with anti-phosphotyrosine antibodies revealed that insulin receptor autophosphorylation and subsequent tyrosine phosphorylation of insulin receptor substrate-1 occurred normally in cells exposed to indinavir (Fig. 2A). As the metabolic effects of insulin require PI 3-kinase activation (22, 23), the in vivo phosphorylation status of the downstream Akt kinase was assessed using phospho-Akt-specific antibodies. Indinavir was found to have no effect on the insulin-stimulated phosphorylation of Akt on threonine 308 or serine 473 (Fig. 2B), thus demonstrating that the PI 3-kinase signaling pathway remained intact. Insulin acutely stimulates glucose uptake in muscle and fat cells by triggering the translocation of intracellularly sequestered glucose transporters, predominantly the Glut4 transporter isoform, to the plasma membrane (32). 3T3-L1 adipocytes express Glut1 and Glut4 (25, 28), and both of these transporter isoforms appeared to translocate properly to the cell surface in response to insulin despite the presence of 100 µM indinavir. The glucose transporter content in the PM fractions detected by isoform-specific antibodies increased with insulin by 81 and 63% for Glut1, and by 36 and 38% for Glut4 in control and indinavir-treated cells, respectively. Concomitantly, the transporter content in the low density microsome (LDM) fractions decreased by 37 and 48% for Glut1, and by 21 and 19% for Glut4 in control and indinavir-treated cells, respectively (Fig. 2C). Confocal immunofluorescence microscopy of whole cells and plasma membrane "sheets" also showed that the subcellular distribution of glucose transporters was unchanged in indinavir-treated samples relative to control cells. Both control and indinavir-treated cells exhibited increased Glut1 and Glut4 staining at the plasma membrane upon stimulation with insulin (Fig. 2D). The rapid onset of inhibition observed in the glucose uptake assay (Fig. 1), in which indinavir was added to the cells after sufficient time had elapsed for the majority of the transporters to reach the plasma membrane following insulin stimulation (33-35), is consistent with indinavir acting at a site subsequent to the translocation of transporters to the plasma membrane. Additionally, the extent of inhibition of transport activity did not change if indinavir was added either before or after 20 min of insulin stimulation (data not shown).

View larger version (48K): [in this window] [in a new window]   Fig. 2.   Indinavir does not affect insulin signaling or glucose transporter translocation. A, mature 3T3-L1 adipocytes were treated with or without 100 µM indinavir for 4 h in serum-free DMEM. Cells were then stimulated with or without 1 µM insulin for 20 min and subcellular fractions were isolated. Plasma membrane (PM), low density microsome (LDM), and cytosol (CYT) fractions were subjected to immunoblot analysis using anti-phosphotyrosine antibodies. The positions of the tyrosine-phosphorylated insulin receptor (IR) and insulin receptor substrate-1 (IRS-1) are indicated by arrows. B, whole cell 3T3-L1 adipocyte lysates from the same samples as above were subjected to immunoblot analysis using anti-phospho Akt antibodies that recognize Akt phosphorylated on threonine 308 and serine 473. C, Glut1 and Glut4 contents in the PM and LDM fractions from the same samples as above were visualized by immunoblot using isoform-specific polyclonal antibodies. D, confocal immunofluorescence micrographs of whole cells (WC) and PM sheets. 3T3-L1 adipocytes were grown on coverslips and treated with or without 100 µM indinavir for 4 h in serum-free DMEM. After treatment with or without 1 µM insulin for 20 min, cells were either fixed immediately or sonicated to prepare PM sheets. Isoform-specific polyclonal antibodies were used to visualize the subcellular distributions of Glut1 and Glut4.

Glut1 and Glut4 were heterologously expressed in X. laevis oocytes by microinjection of their respective mRNA to test the possibility that indinavir might be directly inhibiting the intrinsic transport activity of glucose transporters. Indinavir at 100 µM had no effect on Glut1 activity in Xenopus oocytes. Remarkably, however, the activity of Glut4 expressed in oocytes was inhibited by 45% at the maximal dose of indinavir tested (100 µM), an effect of comparable magnitude to that observed in insulin-stimulated 3T3-L1 adipocytes (Fig. 3A). Ritonavir and amprenavir also selectively inhibited Glut4 by 54 and 42%, respectively (Fig. 3B). The data obtained in Xenopus oocytes are consistent with what is observed in 3T3-L1 adipocytes, in which basal (indinavir-resistant) and insulin-stimulated (indinavir-inhibitable) glucose uptake are largely mediated by Glut1 and Glut4, respectively (25).

View larger version (20K): [in this window] [in a new window]   Fig. 3.   Inhibition of glucose uptake in X. laevis oocytes by HIV protease inhibitors. [3H]2-Deoxyglucose uptake measurements in Xenopus oocytes heterologously expressing either Glut1 or Glut4 were performed in Barth's saline at 22 °C for 30 min. A, indinavir sulfate was added to the assay mixture immediately prior to the uptake measurement at the indicated final concentrations (µM). The data represent the mean uptake from 15-20 oocytes ± S.E. * indicates p < 0.01 compared with control (ANOVA with Fisher's PLSD posthoc analysis). B, 50 µM ritonavir, indinavir, or amprenavir was added to each assay mixture immediately prior to uptake measurement. The data are normalized to the uptake value observed in untreated control oocytes. * indicates p < 0.0001 compared with control (ANOVA with Fisher's PLSD posthoc analysis).

From the above data, we conclude that HIV protease inhibitors unexpectedly act as potent, isoform-specific inhibitors of the transport function of the Glut4 glucose transporter. This is the first demonstration that pharmacologic manipulation of glucose transport is feasible in a selective manner. An agent that can reversibly induce an insulin-resistant state would be a very useful tool in developing model systems that mimic the pathogenesis of type 2 diabetes.

Glut4 is predominantly expressed in tissues responsible for the bulk of whole body glucose disposal (skeletal/cardiac muscle and fat) (18-21) and is believed to be the principal transporter isoform mediating insulin-stimulated glucose uptake at these sites. As glucose transport is the rate-limiting step for whole body glucose disposal in rodents (36-38) and in humans (39), the inhibitory effect of retroviral protease inhibitors on Glut4 is therefore likely to be the direct cause of insulin resistance observed in HIV patients receiving this class of drugs. In predisposed individuals, diabetes can result after pancreatic  cells fail to compensate for the insulin resistance. A recent clinical study employing a longitudinal design comparing fasting glucose and insulin levels before and after administration of protease inhibitor therapy demonstrated that insulin resistance is apparent after a relatively short period of time (an average of 3.4 months between measurements) before significant changes in body weight and fat distribution occur (40). The fact that insulin resistance appears to precede the manifestation of lipodystrophy is consistent with our hypothesis that indinavir directly causes insulin resistance through its effect on Glut4, rather than insulin resistance developing secondary to the lipodystrophy. We predict that insulin resistance may occur much earlier than reported thus far, perhaps even immediately upon initiation of protease inhibitor therapy. Moreover, if our hypothesis is correct, insulin resistance should be maximal when in vivo protease inhibitor concentrations are maximal. Thus, depending on the dosing regimen and the pharmacokinetic characteristic of the protease inhibitor used, simple measurements of fasting glucose and insulin levels may be underestimating the true extent of insulin resistance that actually occurs.

A knockout mouse that lacks Glut4 is insulin-resistant, and interestingly, almost devoid of fat tissue (41). Thus, Glut4 activity per se may somehow be required for adipogenesis. If this is true, the protease inhibitor's direct effect on Glut4 may account for the clinically observed lipodystrophy in addition to the insulin resistance. Recent reports that HIV protease inhibitors interfere with adipogenesis in cultured cell models (42, 43) do not contradict this scenario. HIV patients treated with protease inhibitors show a characteristic loss of adipose tissues at peripheral sites as opposed to the abdomen (44). We speculate that peripheral adipocytes preferentially synthesize lipid de novo from blood glucose, whereas abdominal adipocytes may obtain their lipid primarily from circulating triglycerides.

As retroviral protease inhibitors play a vital role in prolonging the lifespan of HIV patients and are often administered over an extended period of time, the metabolic side effects and their chronic consequences are likely to be more prevalent in the future. Further drug development may be necessary to design new compounds that maintain the efficacy in the management of HIV infection, but that also minimize the detrimental effect on the glucose transport system observed in this study.

	ACKNOWLEDGEMENTS

We thank L. A. Nolte, J. O. Holloszy, and Y. Murata for helpful discussions.

	FOOTNOTES

^* This work was supported in part by National Institutes of Health Grant DK38495 and by the Diabetes Training and Research Center at Washington University School of Medicine.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ These authors contributed equally to this work.

To whom all correspondence should be addressed: Dept. of Cell Biology and Physiology, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110. Tel.: 314-362-4160; Fax: 314-362-7463; E-mail: mike@cellbio.wustl.edu.

Published, JBC Papers in Press, May 9, 2000, DOI 10.1074/jbc.C000228200

	ABBREVIATIONS

The abbreviations used are: HIV, human immunodeficiency virus; PI, phosphatidylinositol; DMEM, Dulbecco's modified Eagle's medium; PM, plasma membrane; ANOVA, analysis of variance; PLSD, protected least square difference; LDM, low density microsome.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS AND DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. K. Grinspoon, C. Grunfeld, D. P. Kotler, J. S. Currier, J. D. Lundgren, M. P. Dube, S. E. Lipshultz, P. Y. Hsue, K. Squires, M. Schambelan, et al. State of the Science Conference: Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS: Executive Summary Circulation, July 8, 2008; 118(2): 198 - 210. [Full Text] [PDF]

				P. W. Hruz, Q. Yan, H. Struthers, and P. Y. Jay HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy FASEB J, July 1, 2008; 22(7): 2161 - 2167. [Abstract] [Full Text] [PDF]

				M. Kratz, J. Q. Purnell, P. A. Breen, K. K. Thomas, K. M. Utzschneider, D. B. Carr, S. E. Kahn, J. P. Hughes, E. A. Rutledge, B. Van Yserloo, et al. Reduced Adipogenic Gene Expression in Thigh Adipose Tissue Precedes Human Immunodeficiency Virus-Associated Lipoatrophy J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 959 - 966. [Abstract] [Full Text] [PDF]

				M. J. Carper, W. T. Cade, M. Cam, S. Zhang, A. Shalev, K. E. Yarasheski, and S. Ramanadham HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus Am J Physiol Endocrinol Metab, March 1, 2008; 294(3): E558 - E567. [Abstract] [Full Text] [PDF]

				K. Samaras Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection J. Antimicrob. Chemother., February 1, 2008; 61(2): 238 - 245. [Abstract] [Full Text] [PDF]

				E. Gkrania-Klotsas and A.-E. Klotsas HIV and HIV treatment: effects on fats, glucose and lipids Br. Med. Bull., December 1, 2007; 84(1): 49 - 68. [Abstract] [Full Text] [PDF]

				M. Guffanti, A. Caumo, L. Galli, A. Bigoloni, A. Galli, G. Dagba, A. Danise, L. Luzi, A. Lazzarin, and A. Castagna Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects Eur. J. Endocrinol., April 1, 2007; 156(4): 503 - 509. [Abstract] [Full Text] [PDF]

				S. S. Shankar, R. V. Considine, J. C. Gorski, and H. O. Steinberg Insulin sensitivity is preserved despite disrupted endothelial function Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E691 - E696. [Abstract] [Full Text] [PDF]

				C. G. Morse and J. A. Kovacs Metabolic and skeletal complications of HIV infection: the price of success. JAMA, August 16, 2006; 296(7): 844 - 854. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Aspects of type 2 diabetes and related insulin-resistant States. Diabetes Care, March 1, 2006; 29(3): 732 - 740. [Full Text] [PDF]

				E. Aghdassi, I. E. Salit, L. Fung, L. Sreetharan, S. Walmsley, and J. P. Allard Is Chromium an Important Element in HIV-Positive Patients with Metabolic Abnormalities? An Hypothesis Generating Pilot Study. J. Am. Coll. Nutr., February 1, 2006; 25(1): 56 - 63. [Abstract] [Full Text] [PDF]

				S. B. Haugaard, O. Andersen, S. Madsbad, C. Frosig, J. Iversen, J. O. Nielsen, and J. F.P. Wojtaszewski Skeletal Muscle Insulin Signaling Defects Downstream of Phosphatidylinositol 3-Kinase at the Level of Akt Are Associated With Impaired Nonoxidative Glucose Disposal in HIV Lipodystrophy Diabetes, December 1, 2005; 54(12): 3474 - 3483. [Abstract] [Full Text] [PDF]

				Error in Renumbering References in Text and Reference List in: Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study Arch Intern Med, November 28, 2005; 165(21): 2541 - 2541. [Full Text] [PDF]

				A. K. Gupta, G. J. Cerniglia, R. Mick, W. G. McKenna, and R. J. Muschel HIV Protease Inhibitors Block Akt Signaling and Radiosensitize Tumor Cells Both In vitro and In vivo Cancer Res., September 15, 2005; 65(18): 8256 - 8265. [Abstract] [Full Text] [PDF]

				L. Q. Hong-Brown, A. M. Pruznak, R. A. Frost, T. C. Vary, and C. H. Lang Indinavir alters regulators of protein anabolism and catabolism in skeletal muscle Am J Physiol Endocrinol Metab, September 1, 2005; 289(3): E382 - E390. [Abstract] [Full Text] [PDF]

				J. L. Park, R. D. Loberg, D. Duquaine, H. Zhang, B. K. Deo, N. Ardanaz, J. Coyle, K. B. Atkins, M. Schin, M. J. Charron, et al. GLUT4 Facilitative Glucose Transporter Specifically and Differentially Contributes to Agonist-Induced Vascular Reactivity in Mouse Aorta Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1596 - 1602. [Abstract] [Full Text] [PDF]

				D. C. Adler-Wailes, H. Liu, F. Ahmad, N. Feng, C. Londos, V. Manganiello, and J. A. Yanovski Effects of the Human Immunodeficiency Virus-Protease Inhibitor, Ritonavir, on Basal and Catecholamine-Stimulated Lipolysis J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3251 - 3261. [Abstract] [Full Text] [PDF]

				R. A. Parker, O. P. Flint, R. Mulvey, C. Elosua, F. Wang, W. Fenderson, S. Wang, W.-P. Yang, and M. A. Noor Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome Activity and Glucose Transport by HIV Protease Inhibitors Mol. Pharmacol., June 1, 2005; 67(6): 1909 - 1919. [Abstract] [Full Text] [PDF]

				T. T. Brown, S. R. Cole, X. Li, L. A. Kingsley, F. J. Palella, S. A. Riddler, B. R. Visscher, J. B. Margolick, and A. S. Dobs Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study Arch Intern Med, May 23, 2005; 165(10): 1179 - 1184. [Abstract] [Full Text] [PDF]

				S. Grinspoon and A. Carr Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults N. Engl. J. Med., January 6, 2005; 352(1): 48 - 62. [Full Text] [PDF]

				S. B Haugaard, O. Andersen, F. Dela, J. J. Holst, H. Storgaard, M. Fenger, J. Iversen, and S. Madsbad Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic {beta}-cells Eur. J. Endocrinol., January 1, 2005; 152(1): 103 - 112. [Abstract] [Full Text] [PDF]

				A. Bitnun, E. Sochett, P. T. Dick, T. To, C. Jefferies, P. Babyn, J. Forbes, S. Read, and S. M. King Insulin Sensitivity and {beta}-Cell Function in Protease Inhibitor-Treated and -Naive Human Immunodeficiency Virus-Infected Children J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 168 - 174. [Abstract] [Full Text] [PDF]

				J. Hertel, H. Struthers, C. B. Horj, and P. W. Hruz A Structural Basis for the Acute Effects of HIV Protease Inhibitors on GLUT4 Intrinsic Activity J. Biol. Chem., December 31, 2004; 279(53): 55147 - 55152. [Abstract] [Full Text] [PDF]

				M Schutt, J Zhou, M Meier, and H H Klein Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells J. Endocrinol., December 1, 2004; 183(3): 445 - 454. [Abstract] [Full Text] [PDF]

				L. Q. Hong-Brown, C. R. Brown, and C. H. Lang Indinavir impairs protein synthesis and phosphorylations of MAPKs in mouse C2C12 myocytes Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1482 - C1492. [Abstract] [Full Text] [PDF]

				M. van der Valk, G. Allick, G. J. Weverling, J. A. Romijn, M. T. Ackermans, J. M. A. Lange, B. L. F. van Eck-Smit, C. van Kuijk, E. Endert, H. P. Sauerwein, et al. Markedly Diminished Lipolysis and Partial Restoration of Glucose Metabolism, without Changes in Fat Distribution after Extended Discontinuation of Protease Inhibitors in Severe Lipodystrophic Human Immunodeficient Virus-1-Infected Patients J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3554 - 3560. [Abstract] [Full Text] [PDF]

				C. Hadigan, S. Yawetz, A. Thomas, F. Havers, P. E. Sax, and S. Grinspoon Metabolic Effects of Rosiglitazone in HIV Lipodystrophy: A Randomized, Controlled Trial Ann Intern Med, May 18, 2004; 140(10): 786 - 794. [Abstract] [Full Text] [PDF]

				K. E. Hadri, M. Glorian, C. Monsempes, M.-N. Dieudonne, R. Pecquery, Y. Giudicelli, M. Andreani, I. Dugail, and B. Feve In Vitro Suppression of the Lipogenic Pathway by the Nonnucleoside Reverse Transcriptase Inhibitor Efavirenz in 3T3 and Human Preadipocytes or Adipocytes J. Biol. Chem., April 9, 2004; 279(15): 15130 - 15141. [Abstract] [Full Text] [PDF]